Current stock page

Stock Analysis

Precigen, Inc. (PGEN) Stock Analysis

Precigen, Inc. (PGEN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PGEN Stock Analysis Summary

Precigen, Inc. (PGEN) currently has an AIQ Score of 55/100, indicating a neutral setup. Value is the strongest factor at 63/100. Risk is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

PGEN at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$4.54
AIQ Score55/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.63B
P/E Ratio (TTM)66.47
Forward P/E—
EPS (Q3 FY2026)$0.10
Revenue (Q3 FY2026)$74.15M
Dividend Yield (TTM)0.00%
Beta1.62
Volume3.78M
52-week range$3.04-$8.98
RSI 1434.19
50-Day SMA$6.74
200-Day SMA$5.28
Analyst Price Target$12.00
Next EarningsMar 2, 2027
As of Nov 13, 2026 · Market close

PGENPrecigen, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$4.54−$0.12 (−2.58%)

Latest quote

  • Momentum
    55
  • Value
    63
  • Quality
    60
  • Risk resilience
    31
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

PGEN Stock Analysis Summary

Precigen, Inc. (PGEN) currently has an AIQ Score of 55/100, indicating a neutral setup. Value is the strongest factor at 63/100. Risk resilience is the weakest current factor at 31/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, PGEN has AIQ Score of 55/100 with Value base of 63/100 and fading Risk resilience at 31/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Value (63/100) leads while Risk resilience (31/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.58% stock move · PGEN classified in Biotechnology.

Current Evidence

NeutralPGEN is in a neutral AIQ regime; Value is the strongest visible factor at 63/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PGEN Bullish or Bearish Right Now?

PGEN currently has a neutral overall setup. Value is the strongest factor at 63/100, while Risk Resilience is weakest at 31/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Analyst target implies +164.32% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 31/100.
  • - Price is -13.99% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (37 vs 2).

Current Consensus

PGEN's Technical Analysis Consensus is currently Strong Sell, with 2 buy, 7 neutral, and 37 sell votes. PGEN's 14-day RSI is 34.19, which places the stock in a weaker momentum range. PGEN's beta is 1.62, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in PGEN?

The largest recent change in PGEN is Momentum moving down by 21.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-7.0
Momentum
-21.0
Quality
+1.0
Risk
+0.0

What Would Change the PGEN Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PGEN Decision Framework

Public evidence layers, setup checks, and risk context for Precigen, Inc..

Precigen, Inc. (PGEN) Stock Analysis

Precigen, Inc. has an AIQ Score of 55/100 in a Neutral regime. Value is strongest at 63/100. Beta is 1.62, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPGEN is in a Neutral AIQ regime with score 55/100.
Signal ConflictThe primary conflict is that value leads at 63/100 while risk lags at 31/100.
Factor EvidenceMomentum 55/100 · Value 63/100 · Quality 60/100 · Risk 31/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthWait

Value is the strongest factor at 63/100.

TimingWait

Momentum is 55/100 and RSI (14) is 34.2.

Regime fitWait

PGEN is in a Neutral regime at 55/100.

Risk controlFail

Risk factor is 31/100 with beta 1.62 and annual volatility 85.43%.

ConflictWait

Current conflict: value leads at 63/100 while risk lags at 31/100.

AIQ Score
55/100
Price
$4.54
Beta
1.62
RSI (14)
34.2

PGEN Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PGEN Fundamentals

PGEN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$74.15M
Net income
$35.77M
Free cash flow
$11.45M
View full PGEN fundamental analysis

PGEN Technical Analysis

PGEN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
34.19
Price vs SMA-50
-32.65%
View full PGEN technical analysis

PGEN Stock Catalysts

Track PGEN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 2, 2027
Analyst target
$12.00
News items
5
View PGEN earnings and stock catalysts

PGEN Dividend Analysis

PGEN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PGEN dividend history and analysis

PGEN Financial Data

PGEN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$74.15M
EPS
$0.10
Periods
8
View PGEN financials

PGEN Risk Analysis

PGEN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.62
Risk score
31/100
1Y volatility
85.43%
View PGEN risk analysis

PGEN Stock News

PGEN stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read PGEN stock news

PGEN vs Biotechnology Peers

Current peer cohort: PGEN · PRAX · PTGX · PVLA · QURE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PGEN
Current stock
55/10063/10055/10031/1000.5785.43%Current
PRAX
Praxis Precision Medicines, Inc.
57/100—48/10047/1001.1375.11%PGEN vs PRAX
PTGX
Protagonist Therapeutics, Inc.
73/10072/10070/10070/1001.2440.11%PGEN vs PTGX
PVLA
Palvella Therapeutics, Inc.
70/100—84/10047/1001.1284.47%PGEN vs PVLA
QURE
uniQure N.V.
39/10038/10041/10031/1000.39132.25%PGEN vs QURE
Pairwise Compare links: PRAX · PTGX · PVLA · QUREPGEN vs PRAXPGEN vs PTGXPGEN vs PVLAPGEN vs QURECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PGEN stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PGEN: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
66.47
As of Nov 13, 2026
Revenue growth
2437.58%
Gross margin
91.01%
Current debt / equity
1.18
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$74.15M
Quarter net income
$35.77M
Quarter free cash flow
$11.45M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
34.19
MACD
-0.69

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
31/100
Beta
1.62
Annual volatility
85.43%
Max drawdown
-50.70%

PGEN Stock FAQ

What is PGEN stock price today?

Precigen, Inc.'s current stock price is $4.54. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PGEN bullish or bearish right now?

PGEN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PGEN's market cap?

PGEN's market cap is $1.63B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PGEN's current P/E ratio?

PGEN's current P/E ratio is 66.47 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PGEN's RSI?

PGEN's 14-day RSI is 34.19 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PGEN above its 50-day and 200-day moving averages?

PGEN is -32.65% from its 50-day SMA and -13.99% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PGEN's next earnings date?

PGEN's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PGEN pay a dividend?

PGEN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.